Investors should monitor the upcoming 16-week data readout for ORKA-001 in 2Q 2026 as a key catalyst; the accelerated timeline may signal strong trial performance and could positively impact sentiment if results are robust.
Price Chart
Executive Summary
Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479.6 million in cash and advancement of its two lead programs: ORKA-001 and ORKA-002. Enrollment in the EVERLAST-A trial for ORKA-001 completed ahead of schedule, with 16-week data now expected in 2Q 2026. The Phase 2 ORCA-SURGE trial for ORKA-002 in psoriasis has been initiated, with data anticipated in 2027.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $479.6 million as of December 31, 2025.
- Net loss was $29.6 million in Q4 2025 and $105.4 million for the full year 2025.
- R&D expenses were $27.6 million in Q4 2025 and $100.6 million for the full year 2025.
- Enrollment in EVERLAST-A (ORKA-001) completed in December 2025; 16-week data expected in 2Q 2026.
- ORCA-SURGE Phase 2 trial for ORKA-002 in psoriasis initiated in February 2026, with data expected in 2027.
Financial Impact
Increased R&D and G&A spending led to higher net loss in 2025 vs. prior period, but strong cash position supports continued development.
Risk Factors
- Clinical development risk: Data from ORKA-001 and ORKA-002 may not meet efficacy or safety expectations.
- Dilution risk: Future capital raises may be necessary beyond 2027, depending on burn rate and development costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access